Metabolite Identification and Profiling in Stroke Drug Discovery and Development

Drug metabolism may lead to the formation of metabolites that may be pharmacologically active or cause adverse reactions. Metabolite identification and analysis is now a routine part of the lead compound optimization and subsequent development process. Analyzing and characterizing metabolites is a critical step in supporting stroke drug discovery, helping to understand clearance mechanisms and address the presence of potentially active or reactive metabolites. In addition, it can help researchers look at metabolites that are disproportionately or uniquely present in stroke compounds to better understand the molecule's biotransformation capabilities. In summary, metabolite identification and analysis can help optimize the PK, PD, and safety of stroke drug candidates.

Fig. 1. Major utilities of metabolite identification and profiling in drug discovery. (Zhang et al., 2009)

Custom Metabolite Identification and Profiling Services

Ace Therapeutics provides reliable metabolite identification and profiling services to characterize the metabolites of your stroke drug candidates to support your stroke drug discovery and development programs. Our team of experts conducts qualitative and quantitative studies on the metabolic fate of stroke drugs, involving metabolite profiling and structural elucidation, metabolic pathway profiling, and determination of relative metabolite abundance. We can offer a range of customized services to meet your needs.

Ace Therapeutics utilizes advanced high-resolution LC-MS and LC-MS/MS technologies to perform metabolite identification studies on in vitro samples and in vivo samples from animal studies in the early stage of stroke drug development.

In Vitro Metabolite Identification and Analysis

Our in vitro metabolic profiling and characterization analyses provide a rapid readout of the metabolism of stroke drugs in the early and preclinical stages of development.

• Identifying metabolic soft spots
• Screening reactive metabolites
• Creating cross-species comparisons to guide toxicology species selection

In Vivo Metabolite Identification and Analysis

Our in vivo metabolite analysis and characterization studies help our clients to further identify metabolites formed after the distribution of stroke drugs to understand the metabolism of the drug in the preclinical stage.

• Assessing metabolite exposure and metabolic clearance pathways in animal models of stroke
• Evaluating relative exposure to metabolites in preclinical stroke models to determine the appropriateness of the selected toxicology species

Our Advantages

• We can rapidly characterize stroke drug metabolites to provide support for PD, PK and TK data.
• Our LC-MS/MS identifies metabolites at high resolution for improved sensitivity and enhanced structural characterization.
• We provide critical information on the formation of stroke drug metabolites and comparison of drug metabolic pathways in different species.
• We can study stroke drug metabolites in in vitro and in vivo samples.
• We also offer a range of metabolite analysis services on request.

Ace Therapeutics offers comprehensive metabolite identification and profiling services in biological matrices to support stroke drug discovery and safety studies. Our flexible, customized metabolite identification and analysis solutions are designed to meet your needs, either as part of a stroke drug development program or as a stand-alone study. If you are interested in our services, please do not hesitate to contact us!

1. Zhang, Z., et al. (2009). Metabolite identification and profiling in drug design: current practice and future directions. Current pharmaceutical design, 15(19), 2220-2235.